JP7439096B2 - 疼痛を処置するためにフェノキシプロピルアミン化合物を使用する方法 - Google Patents

疼痛を処置するためにフェノキシプロピルアミン化合物を使用する方法 Download PDF

Info

Publication number
JP7439096B2
JP7439096B2 JP2021536676A JP2021536676A JP7439096B2 JP 7439096 B2 JP7439096 B2 JP 7439096B2 JP 2021536676 A JP2021536676 A JP 2021536676A JP 2021536676 A JP2021536676 A JP 2021536676A JP 7439096 B2 JP7439096 B2 JP 7439096B2
Authority
JP
Japan
Prior art keywords
pain
compound
per day
subject
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021536676A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021536506A5 (https=
JP2021536506A (ja
Inventor
レミ・ルスリンガー
ナディネ・ノエル
ジェイ・サウード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of JP2021536506A publication Critical patent/JP2021536506A/ja
Publication of JP2021536506A5 publication Critical patent/JP2021536506A5/ja
Priority to JP2024020391A priority Critical patent/JP2024056875A/ja
Application granted granted Critical
Publication of JP7439096B2 publication Critical patent/JP7439096B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2021536676A 2018-09-04 2019-09-04 疼痛を処置するためにフェノキシプロピルアミン化合物を使用する方法 Active JP7439096B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024020391A JP2024056875A (ja) 2018-09-04 2024-02-14 疼痛を処置するためにフェノキシプロピルアミン化合物を使用する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862726800P 2018-09-04 2018-09-04
US62/726,800 2018-09-04
PCT/US2019/049492 WO2020101790A2 (en) 2018-09-04 2019-09-04 Methods of using a phenoxypropylamine compound to treat pain

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024020391A Division JP2024056875A (ja) 2018-09-04 2024-02-14 疼痛を処置するためにフェノキシプロピルアミン化合物を使用する方法

Publications (3)

Publication Number Publication Date
JP2021536506A JP2021536506A (ja) 2021-12-27
JP2021536506A5 JP2021536506A5 (https=) 2022-09-12
JP7439096B2 true JP7439096B2 (ja) 2024-02-27

Family

ID=69641874

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021536676A Active JP7439096B2 (ja) 2018-09-04 2019-09-04 疼痛を処置するためにフェノキシプロピルアミン化合物を使用する方法
JP2024020391A Pending JP2024056875A (ja) 2018-09-04 2024-02-14 疼痛を処置するためにフェノキシプロピルアミン化合物を使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024020391A Pending JP2024056875A (ja) 2018-09-04 2024-02-14 疼痛を処置するためにフェノキシプロピルアミン化合物を使用する方法

Country Status (15)

Country Link
US (2) US11766430B2 (https=)
EP (1) EP3846812A2 (https=)
JP (2) JP7439096B2 (https=)
KR (1) KR102886521B1 (https=)
CN (1) CN112955145A (https=)
AU (2) AU2019381269B2 (https=)
BR (1) BR112021004030A2 (https=)
CA (1) CA3110652A1 (https=)
CL (1) CL2021000531A1 (https=)
GB (1) GB2591937B (https=)
IL (1) IL281166B2 (https=)
MA (1) MA53565A (https=)
MX (1) MX2021002590A (https=)
UA (1) UA129837C2 (https=)
WO (1) WO2020101790A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021026480A2 (pt) 2019-06-28 2022-02-08 Univ Texas Método para reconstituir anamicina, método para preparar uma dose eficaz de uma formulação lipossômica reconstituída de anamicina e método para tratar câncer
JP2024520463A (ja) 2021-05-24 2024-05-24 メディコン ファーマシューティカルズ，インコーポレイテッド 化学療法誘発性末梢神経障害に関連する疼痛の処置
EP4272826A3 (en) * 2021-05-24 2024-01-17 Medicon Pharmaceuticals, Inc. Treating pain associated with diabetic peripheral neuropathy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020165263A1 (en) 2001-02-20 2002-11-07 T.G. Dinan Treatment of fibromyalgia and related fatigue syndromes using antagonists or paritcal agonists of 5HT1a receptors
WO2017205399A1 (en) 2016-05-25 2017-11-30 Minerva Neurosciences, Inc. (2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4207343A (en) 1978-06-22 1980-06-10 Eli Lilly And Company 1-Phenyl-3-(substituted phenoxy)propylamines
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ES2244438T3 (es) * 1999-05-24 2005-12-16 Mitsubishi Pharma Corporation Compuestos de fenoxipropilamina.
ES2220582T3 (es) 1999-12-20 2004-12-16 Eli Lilly And Company Derivados de piperidina y su uso como antagonistas de receptor de serotonina.
DK1423168T3 (da) * 2001-09-03 2006-05-15 Newron Pharm Spa Farmaceutisk præparat omfattende gabapentin eller en analog deraf og et alfa-aminoamid og dets analgetiske anvendelse
US20040147581A1 (en) 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
SA08280759B1 (ar) 2007-01-10 2011-05-04 سولفاي فارماسوتيكالز بي . في مركبات من عوامل مضادة لشبيه القنب – cb1 ومكونات هيكلية من مثبطات إعادة إمتصاص السيروتونين بأندلابين أو فلوكسامين
TW201039815A (en) 2009-04-13 2010-11-16 Resolvyx Pharmaceuticals Inc Compositions and methods for the treatment of inflammation
RU2424799C1 (ru) 2010-03-29 2011-07-27 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ ФЕДЕРАЛЬНОГО АГЕНТСТВА ПО ЗДРАВООХРАНЕНИЮ И СОЦИАЛЬНОМУ РАЗВИТИЮ" Способ коррекции депрессивных расстройств производными тиетан-1,1-диоксида в эксперименте
DK2948143T3 (da) 2013-01-24 2021-07-26 Minerva Neurosciences Inc Anvendelse af phenoxypropylaminforbindelser til behandling af depression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020165263A1 (en) 2001-02-20 2002-11-07 T.G. Dinan Treatment of fibromyalgia and related fatigue syndromes using antagonists or paritcal agonists of 5HT1a receptors
WO2017205399A1 (en) 2016-05-25 2017-11-30 Minerva Neurosciences, Inc. (2s)-1-[4-(3,4-dichlorophenyl)piperidin-l-yl]-3-[2-(5-methyl-l,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol or its metabolite for treating anxiety disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
British Journal of Pharmacology，2014年，Vol.171, No.3，pp. 636-645
Gastroenterology，2010年，Vol. 138, No. 5, Suppl. 1，pp. S571-S572
Neuropharmacology，2017年，Vol.125，pp. 181-188
Pain，1994年，58(1)，pp. 45-61
Scientific Reports，2013年，3, 1，3377

Also Published As

Publication number Publication date
US11766430B2 (en) 2023-09-26
IL281166A (en) 2021-04-29
KR102886521B1 (ko) 2025-11-17
WO2020101790A3 (en) 2020-07-09
UA129837C2 (uk) 2025-08-20
US20200069672A1 (en) 2020-03-05
IL281166B1 (en) 2025-04-01
AU2025204043A1 (en) 2025-06-19
JP2024056875A (ja) 2024-04-23
WO2020101790A2 (en) 2020-05-22
GB2591937B (en) 2023-06-07
EP3846812A2 (en) 2021-07-14
US20240016790A1 (en) 2024-01-18
MX2021002590A (es) 2021-05-31
CA3110652A1 (en) 2020-05-22
GB202104738D0 (en) 2021-05-19
AU2019381269B2 (en) 2025-03-06
IL281166B2 (en) 2025-08-01
KR20210061357A (ko) 2021-05-27
BR112021004030A2 (pt) 2021-06-22
AU2019381269A1 (en) 2021-03-18
MA53565A (fr) 2021-07-14
CN112955145A (zh) 2021-06-11
GB2591937A (en) 2021-08-11
CL2021000531A1 (es) 2021-10-08
JP2021536506A (ja) 2021-12-27

Similar Documents

Publication Publication Date Title
US20240016790A1 (en) Methods of using a phenoxypropylamine compound to treat pain
RS60152B1 (sr) Tapentadol za sprečavanje i lečenje depresije i anksioznosti
KR20030040201A (ko) 급성 통증, 만성 통증 및/또는 신경병성 통증 및 편두통을치료하기 위한 약학 조성물
WO2016126707A1 (en) Apilimod compositions and methods for using same
EP4512473A2 (en) Methods of treating behavior alterations
CN108463224A (zh) sGC刺激剂用于胃肠功能障碍治疗的应用
ES2649492T3 (es) (S)-pirlindol o sus sales farmacéuticamente aceptables para uso en medicina
CN105209445B (zh) 治疗运动障碍和相关病症的方法
US20170209489A1 (en) Fast acting inhibitor of gastric acid secretion with enhanced activity
WO2016042501A1 (en) Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
EA015483B1 (ru) ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ
US20110244057A1 (en) Combination therapies with topiramate for seizures, restless legs syndrome, and other neurological conditions
RU2797615C2 (ru) Способы применения феноксипропиламинового соединения для лечения боли
TWI874362B (zh) 使用苯氧丙胺化合物治療疼痛的方法
US12139402B2 (en) Pharmaceutical formulations of nitrite and uses thereof
WO2019151409A1 (ja) 鎮痛剤及び鎮静剤
JP2020525548A (ja) 炎症反応を伴う疼痛状態における鎮痛のための末梢限局的二重作用性κおよびδオピオイドアゴニスト
RU2799049C2 (ru) Способы лечения изменений поведения
CA3071804C (en) Use of a kdm1a inhibitor in the treatment of behavior alterations

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20211008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20211008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220902

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230718

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240214

R150 Certificate of patent or registration of utility model

Ref document number: 7439096

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150